Differential expression genes analyzed by cDNA array in the regulation of rat hepatic fibrogenesis
- 10 October 2006
- journal article
- Published by Wiley in Liver International
- Vol. 26 (9) , 1126-1137
Abstract
Abstract: Purpose: To analyze the gene expression pattern in rat hepatic fibrogenesis and further assess the role of some key genes during the pathological process.Methods: Hepatic fibrosis was induced by intraperitoneal injection of dimethylnitrosamine or carbon tetrachloride (CCl4) injection subcutaneously in rats, and identification of the hepatic fibrosis related genes with cDNA microarray was performed. After some key genes up‐regulated during the development of hepatic fibrosis were screened and confirmed, their effects on the function of the activated rat hepatic stellate cells (HSC) were assessed using the small interfering RNA (siRNA) technique.Results: Using an Atlas rat cDNA array, a number of differentially expressed genes in fibrotic liver tissues were identified compared with non‐diseased control. A total of 15 genes predominantly associated with the mitogen‐activated protein kinase (MAPK) signal transduction pathway were upregulated in the fibrotic liver. Immunohistochemical study revealed that the expressions of both extracellular signal‐regulated kinases (ERK) and ribosomal protein S6 kinase (RSK), two of the key genes in the MAPK pathway, were remarkably induced, which was closely correlated to that of collagen types I and III during the development of hepatic fibrosis. Transfection of siRNA targeting ERK1 mRNA (siERK1) into HSC led to a 66% and 72% reduction of ERK1 mRNA and protein expression, respectively. Furthermore, siERK1 exerted the inhibition of the proliferation of HSC, accompanied by the induction of HSC apoptosis and reduction of collagen types I and III. In addition, siERK1 abolished the effect of platelet‐derived growth factor‐BB on the proliferation of HSC.Conclusions: The present study provided strong evidence for the participation of the MAPK pathway in the pathogenesis of hepatic fibrosis. Selective targeting of ERK1 inhibitors to HSC might present as a novel strategy for the treatment of hepatic fibrosis.Keywords
This publication has 41 references indexed in Scilit:
- Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes.Liver International, 2005
- Cell-type-specific activation of mitogen-activated protein kinases in PAN-induced progressive renal disease in ratsBiochemical and Biophysical Research Communications, 2004
- A gene-expression signature can quantify the degree of hepatic fibrosis in the ratJournal of Hepatology, 2004
- The RNAi revolutionNature, 2004
- The human Delta‐like 1 homologue is implicated in the progression of liver fibrosis in biliary atresiaThe Journal of Pathology, 2004
- Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosisOncogene, 2003
- Analysis of gene expression in carbon tetrachloride-treated rat livers using a novel bioarray technologyThe Pharmacogenomics Journal, 2003
- Gene array analysis and the liverHepatology, 2002
- MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosisThe Journal of Pathology, 2002
- Hepatic Stellate Cells as a Target for the Treatment of Liver FibrosisSeminars in Liver Disease, 2001